| 11. |
- Niemi, MEK, et al.
(författare)
-
- 2021
-
swepub:Mat__t
|
|
| 12. |
- Kanai, M, et al.
(författare)
-
- 2023
-
swepub:Mat__t
|
|
| 13. |
- Björkman, Anne, 1981, et al.
(författare)
-
Plant functional trait change across a warming tundra biome
- 2018
-
Ingår i: Nature. - : Springer Science and Business Media LLC. - 0028-0836 .- 1476-4687. ; 562:7725, s. 57-62
-
Tidskriftsartikel (refereegranskat)abstract
- The tundra is warming more rapidly than any other biome on Earth, and the potential ramifications are far-reaching because of global feedback effects between vegetation and climate. A better understanding of how environmental factors shape plant structure and function is crucial for predicting the consequences of environmental change for ecosystem functioning. Here we explore the biome-wide relationships between temperature, moisture and seven key plant functional traits both across space and over three decades of warming at 117 tundra locations. Spatial temperature–trait relationships were generally strong but soil moisture had a marked influence on the strength and direction of these relationships, highlighting the potentially important influence of changes in water availability on future trait shifts in tundra plant communities. Community height increased with warming across all sites over the past three decades, but other traits lagged far behind predicted rates of change. Our findings highlight the challenge of using space-for-time substitution to predict the functional consequences of future warming and suggest that functions that are tied closely to plant height will experience the most rapid change. They also reveal the strength with which environmental factors shape biotic communities at the coldest extremes of the planet and will help to improve projections of functional changes in tundra ecosystems with climate warming.
|
|
| 14. |
- Bläckberg, Lisa, 1982-, et al.
(författare)
-
Light spread manipulation in scintillators using laser induced optical barriers
- 2018
-
Ingår i: IEEE Transactions on Nuclear Science. - : Institute of Electrical and Electronics Engineers (IEEE). - 0018-9499 .- 1558-1578. ; 65:8, s. 2208-2215
-
Tidskriftsartikel (refereegranskat)abstract
- We are using the Laser Induced Optical Barriers (LIOB) technique to fabricate scintillator detectors with combined performance characteristics of the two standard detector types, mechanically pixelated arrays and monolithic crystals. This is done by incorporation of so-called optical barriers that have a refractive index lower than that of the crystal bulk. Such barriers can redirect the scintillation light and allow for control of the light spread in the detector. Previous work has shown that the LIOB technique has the potential to achieve detectors with high transversal and depth of interaction (DOI) resolution simultaneously in a single-side readout configuration, suitable for high resolution PET imaging. However, all designs studied thus far present edge effect issues similarly as in the standard detector categories. In this work we take advantage of the inherent flexibility of the LIOB technique and investigate alternative barrier patterns with the aim to address this problem. Light transport simulations of barrier patterns in LYSO:Ce, with deeper barrier walls moving towards the detector edge show great promise in reducing the edge effect, however there is a trade-off in terms of achievable DOI information. Furthermore, fabrication and characterization of a 20 mm thick LYSO:Ce detector with optical barriers forming a pattern of 1×1×20mm3 pixel like structures show that light channeling in laser-processed detectors in agreement with optical barriers with refractive index between 1.2 and 1.4 is achievable.
|
|
| 15. |
- Bläckberg, Lisa, 1982-, et al.
(författare)
-
Scintillator-based Photon Counting Detector : is it feasible?
- 2016
-
Ingår i: 2016 IEEE Nuclear Science Symposium, Medical Imaging Conference And Room-Temperature Semiconductor Detector Workshop (Nss/Mic/Rtsd). - 9781509016426 - 9781509016433
-
Konferensbidrag (refereegranskat)abstract
- By utilizing finely pitched scintillator arrays where the scintillator has high atomic number and density, fast decay time, and high light output, realizing a scintillator-based Photon Counting Detector (PCD) is conceptually feasible. Fabrication of fine-pitched scintillator arrays however, has been the bottleneck for realizing such detectors. Combining the novel scintillator fabrication technique called laser-induced optical barriers (LIOB) where optical barriers can be placed inside a transparent crystal and act as a reflector without removing the material, with laser ablation, we are now able to overcome the obstacles for developing scintillator-based PCD. In this regard, we are developing an LYSO-based PCD where the LYSO crystal is laser pixelated to sub-mm pixels. The scintillator array will be coupled to an application specific integrated circuit (ASIC) where each ASIC pixel has built-in photodiode, amplifiers and 3-4 energy windows and their associated counters. We have simulated light transport for different scenarios where the crystal is pixelated by a combination of LIOB and laser cut techniques, where the 2 mm thick crystal is first pixelated by LIOB to a depth and then the rest is pixelated by the ablation technique. We also simulated the fraction of collected light in the same scintillator pixel by modeling various surface properties of the pixel cuts as well as optical barrier surface roughness and refractive index (RI). Simulation results show that up to similar to 70% of the scintillation light will be contained in the same pixel when only using the LIOB technique with barrier refractive index of 1.0. These results suggest that laser processed arrays can potentially change the paradigm in PCD development as they can replace the traditional array production and thus allow for scintillator-based PCD development in a more robust and cost-effective manner.
|
|
| 16. |
- Collij, L. E., et al.
(författare)
-
The amyloid imaging for the prevention of Alzheimer's disease consortium: A European collaboration with global impact
- 2023
-
Ingår i: Frontiers in Neurology. - : Frontiers Media SA. - 1664-2295. ; 13
-
Tidskriftsartikel (refereegranskat)abstract
- BackgroundAmyloid-beta (A beta) accumulation is considered the earliest pathological change in Alzheimer's disease (AD). The Amyloid Imaging to Prevent Alzheimer's Disease (AMYPAD) consortium is a collaborative European framework across European Federation of Pharmaceutical Industries Associations (EFPIA), academic, and 'Small and Medium-sized enterprises' (SME) partners aiming to provide evidence on the clinical utility and cost-effectiveness of Positron Emission Tomography (PET) imaging in diagnostic work-up of AD and to support clinical trial design by developing optimal quantitative methodology in an early AD population. The AMYPAD studiesIn the Diagnostic and Patient Management Study (DPMS), 844 participants from eight centres across three clinical subgroups (245 subjective cognitive decline, 342 mild cognitive impairment, and 258 dementia) were included. The Prognostic and Natural History Study (PNHS) recruited pre-dementia subjects across 11 European parent cohorts (PCs). Approximately 1600 unique subjects with historical and prospective data were collected within this study. PET acquisition with [F-18]flutemetamol or [F-18]florbetaben radiotracers was performed and quantified using the Centiloid (CL) method. ResultsAMYPAD has significantly contributed to the AD field by furthering our understanding of amyloid deposition in the brain and the optimal methodology to measure this process. Main contributions so far include the validation of the dual-time window acquisition protocol to derive the fully quantitative non-displaceable binding potential (BPND), assess the value of this metric in the context of clinical trials, improve PET-sensitivity to emerging A beta burden and utilize its available regional information, establish the quantitative accuracy of the Centiloid method across tracers and support implementation of quantitative amyloid-PET measures in the clinical routine. Future stepsThe AMYPAD consortium has succeeded in recruiting and following a large number of prospective subjects and setting up a collaborative framework to integrate data across European PCs. Efforts are currently ongoing in collaboration with ARIDHIA and ADDI to harmonize, integrate, and curate all available clinical data from the PNHS PCs, which will become openly accessible to the wider scientific community.
|
|
| 17. |
|
|
| 18. |
- Herrick, Ariane L, et al.
(författare)
-
Treatment outcome in early diffuse cutaneous systemic sclerosis : The European Scleroderma Observational Study (ESOS)
- 2017
-
Ingår i: Annals of the Rheumatic Diseases. - : BMJ. - 0003-4967 .- 1468-2060. ; 76:7, s. 1207-1218
-
Tidskriftsartikel (refereegranskat)abstract
- Objectives: The rarity of early diffuse cutaneous systemic sclerosis (dcSSc) makes randomised controlled trials very difficult. We aimed to use an observational approach to compare effectiveness of currently used treatment approaches. Methods: This was a prospective, observational cohort study of early dcSSc (within three years of onset of skin thickening). Clinicians selected one of four protocols for each patient: methotrexate, mycophenolate mofetil (MMF), cyclophosphamide or 'no immunosuppressant'. Patients were assessed three-monthly for up to 24 months. The primary outcome was the change in modified Rodnan skin score (mRSS). Confounding by indication at baseline was accounted for using inverse probability of treatment (IPT) weights. As a secondary outcome, an IPT-weighted Cox model was used to test for differences in survival. Results Of 326 patients recruited from 50 centres, 65 were prescribed methotrexate, 118 MMF, 87 cyclophosphamide and 56 no immunosuppressant. 276 (84.7%) patients completed 12 and 234 (71.7%) 24 months follow-up (or reached last visit date). There were statistically significant reductions in mRSS at 12 months in all groups: -4.0 (-5.2 to -2.7) units for methotrexate, -4.1 (-5.3 to -2.9) for MMF, -3.3 (-4.9 to -1.7) for cyclophosphamide and -2.2 (-4.0 to -0.3) for no immunosuppressant (p value for between-group differences=0.346). There were no statistically significant differences in survival between protocols before (p=0.389) or after weighting (p=0.440), but survival was poorest in the no immunosuppressant group (84.0%) at 24 months. Conclusions: These findings may support using immunosuppressants for early dcSSc but suggest that overall benefit is modest over 12 months and that better treatments are needed.
|
|
| 19. |
- Malzbender, K., et al.
(författare)
-
Validation, Deployment, and Real-World Implementation of a Modular Toolbox for Alzheimer’s Disease Detection and Dementia Risk Reduction: The AD-RIDDLE Project
- 2024
-
Ingår i: Journal of Prevention of Alzheimer's Disease. - 2274-5807 .- 2426-0266. ; 11:2, s. 329 - 338
-
Tidskriftsartikel (refereegranskat)abstract
- The Real-World Implementation, Deployment, and Validation of Early Detection Tools and Lifestyle Enhancement (AD-RIDDLE) project, recently launched with the support of the EU Innovative Health Initiative (IHI) public-private partnership and UK Research and Innovation (UKRI), aims to develop, test, and deploy a modular toolbox platform that can reduce existing barriers to the timely detection, and therapeutic approaches in Alzheimer’s disease (AD), thus accelerating AD innovation. By focusing on health system and health worker practices, AD-RIDDLE seeks to improve and smooth AD management at and between each key step of the clinical pathway and across the disease continuum, from at-risk asymptomatic stages to early symptomatic ones. This includes innovation and improvement in AD awareness, risk reduction and prevention, detection, diagnosis, and intervention. The 24 partners in the AD-RIDDLE interdisciplinary consortium will develop and test the AD-RIDDLE toolbox platform and its components individually and in combination in six European countries. Expected results from this cross-sectoral research collaboration include tools for earlier detection and accurate diagnosis; validated, novel digital cognitive and blood-based biomarkers; and improved access to individualized preventative interventions (including multimodal interventions and symptomatic/disease-modifying therapies) across diverse populations, within the framework of precision medicine. Overall, AD-RIDDLE toolbox platform will advance management of AD, improving outcomes for patients and their families, and reducing costs.
|
|
| 20. |
|
|
